Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Published:2020-03 Issue:3 Volume:21 Page:358-372
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dummer Reinhard,Brase Jan C,Garrett James,Campbell Catarina D,Gasal Eduard,Squires Matthew,Gusenleitner Daniel,Santinami Mario,Atkinson Victoria,Mandalà Mario,Chiarion-Sileni Vanna,Flaherty Keith,Larkin James,Robert Caroline,Kefford Richard,Kirkwood John M,Hauschild Axel,Schadendorf Dirk,Long Georgina V

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

2. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma;Hauschild;J Clin Oncol,2018

3. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018

4. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: updated results from a phase III trial (CheckMate 238);Weber;Proc Am Soc Clin Oncol,2018

5. The new era of adjuvant therapies for melanoma;Eggermont;Nat Rev Clin Oncol,2018

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Therapeutic Treatment Options for In-Transit Metastases from Melanoma;Cancers;2024-09-03

3. Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions;Cancers;2024-07-29

4. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma;New England Journal of Medicine;2024-06-19

5. Unaddressed Challenges in the Treatment of Cutaneous Melanoma?;Medicina;2024-05-28